Alzheimer’s disease (AD) is a major global health challenge, with early and accurate diagnosis being crucial for treatment and prevention. This review highlights the role of cerebrospinal fluid (CSF) and blood biomarkers, focusing on the AT(N) system and emerging markers linked to inflammation, vascular issues, and neurodegeneration. By addressing both the advancements and challenges in biofluid biomarkers, the article provides insights into the future of AD diagnosis and management.

To read the full article, click here: Biofluid biomarkers for Alzheimer’s disease: past, present, and future